KORU Medical Systems Inc (KRMD)

[blue_skies]

@J

The third quarter included some onetime sales which bumped revenue up to $6.6 million. The high sales numbers made other lines in the companies operating matrix look good. The fourth quarter sales will not match those in the third quarter. Expect third quarter sales to come in between 5.6 and 6 million dollars, which is about 7% over Q2. I see Q4 total revenue numbers as disappointing unrealistic investor exceptions. Lower revenue will negatively affect gross margins and EBITDA.

Offsetting this, on the positive side, litigation expenses associated with EMED should be much lower and help net income.

Take away. The stock has had a tremendous run. The story remains the same and the company continues to execute its business plan. Insiders with big holdings are not selling. Increased volume and larger share blocks transactions suggest increased institution activity.

See pull backs to under $5.25 as opportunities to add or initiate positions.

A good management team plus a strong BOD equals rewards for patient investors